In contrast to placebo, MIT administration generated remarkably decreased tumour sizes regardless of the presence of SPINK1 in stromal cells, validating the efficacy of MIT as a cytotoxic agent (Fig. 6b). The gene discussed is SPINK1; the disease is neoplasm.